Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

被引：0
|
作者：
Bell, Jill A. [1 ]
Cherepanov, Dasha [1 ]
Revicki, Dennis [2 ]
Speck, Rebecca M. [2 ]
Swett, Laura [2 ]
Stumpo, Kate [1 ]
Rong, Yuanxin [1 ]
Gordon, Leo I. [3 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Evidera PPD, Bethesda, MD USA
[3] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
QUALITY OF LIFE RESEARCH | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
B204.2
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [21] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [22] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
    Maziarz, Richard T.
    Schuster, Stephen J.
    Romanov, Vadim V.
    Rusch, Elisha S.
    Signorovitch, James
    Ericson, Solveig G.
    Maloney, David G.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [23] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
    Longcor, J.
    Oliver, K.
    Friend, J.
    Callandar, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
  • [24] Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
    Hawkes, Eliza Anne
    Manos, Kate
    Chong, Geoffrey
    Palmer, Jodie
    MacManus, Michael Patrick
    Keane, Colm
    Scott, Andrew Mark
    Shortt, Jake
    Ritchie, David
    Churilov, Leonid
    Johnston, Laura
    Witkowski, Tom
    Barraclough, Allison Anne
    Lee, Sze Ting
    Lin, Wendi
    Koldej, Rachel
    Khor, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [26] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [28] Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Yung, Mallory
    Schnell, Frederick
    Vukcevic, Mirko
    Kurukulasuriya, Nuwan C.
    BLOOD, 2021, 138 : 1928 - +
  • [29] EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL
    Vose, Julie
    Vitolo, Umberto
    Lugtenburg, Pieternella
    Chamuleau, Martine E. D.
    Linton, Kim M.
    Thieblemont, Catherine
    Sonnevi, Kristina
    Jurczak, Wojciech
    Olszewski, Adam J.
    Awan, Farrukh Tauseef
    Okada, Craig Y.
    Feldman, Tatyana A.
    Hutchings, Martin
    Favaro, Elena
    Hoehn, Daniela
    Li, Zhu
    Conlon, Rebekah
    Sancho, Juan-Manuel
    Chavez, Julio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma
    Maurer, Matthew J.
    Jakobsen, Lasse H.
    Mwangi, Raphael
    Schmitz, Norbert
    Farooq, Umar
    Flowers, Cristopher R.
    de Nully Brown, Peter
    Thompson, Carrie A.
    Frederiksen, Henrik
    Cunningham, David
    Jorgensen, Judit
    Poeschel, Viola
    Nowakowski, Grzegorz
    Seymour, John F.
    Merli, Francesco
    Haioun, Corinne
    Ghesquieres, Herve
    Ziepert, Marita
    Tilly, Herve
    Salles, Gilles
    Shi, Qian
    El-Galaly, Tarec C.
    Habermann, Thomas M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : 599 - 605
12345